Summary:

- This article discusses the results of a Phase 3 clinical trial for Merck's investigational oral PCSK9 inhibitor, enlicitide decanoate, which was found to significantly reduce LDL-C (bad cholesterol) levels in patients.

- PCSK9 inhibitors are a class of medications that work by blocking a protein called PCSK9, which helps remove LDL-C from the bloodstream. Lowering LDL-C is important for reducing the risk of heart disease.

- The CORALREEF Lipids trial showed that enlicitide decanoate was effective in lowering LDL-C levels compared to placebo, with a favorable safety profile. This suggests it could be a promising new oral treatment option for patients with high cholesterol.